69 215

Cited 20 times in

Phase II trial of rituximab plus CVP combination chemotherapy for advanced stage marginal zone lymphoma as a first-line therapy: Consortium for Improving Survival of Lymphoma (CISL) study

Authors
Kang, HJ; Kim, WS; Kim, SJ; Lee, JJ; Yang, DH; Kim, JS; Lee, SR; Lee, GW; Kim, HJ; Kim, HY; Oh, SY; Kim, HC; Eom, HS; Chung, J; Park, J; Suh, C; Ryoo, BY
Citation
Annals of hematology, 91(4):543-551, 2012
Journal Title
Annals of hematology
ISSN
0939-55551432-0584
Abstract
We conducted a multicenter, phase II trial to investigate the efficacy and safety of rituximab plus CVP (R-CVP) combination therapy for patients with previously untreated stage III or IV marginal zone lymphoma (MZL). The treatment consisted of rituximab 375 mg/m(2), cyclophosphamide 750 mg/m(2) and vincristine 1.4 mg/m(2) (maximum 2.0 mg) being given intravenously on day 1 and oral prednisolone 100 mg on days 1-5. The treatment was repeated every 3 weeks and this was continued for six or eight cycles. Forty-two patients were enrolled from 13 institutes in Korea. Among them, two patients were dropped after the first and second cycles of chemotherapy, respectively, without evaluation. The 40 patients received a total of 287 cycles of R-CVP chemotherapy. The overall response rate was 88% (95% CI, 77-98%) with 24 complete responses (60%). The median duration of response was 28.3 months. After a median follow-up of 38.2 months, the estimated 3-year progression-free survival and overall survival were 59% and 95%, respectively. There were 30/287 cycles (11%) and 5/287 cycles (2%) of grade 3 or 4 neutropenia and febrile neutropenia, respectively. The R-CVP regimen can be an effective and tolerable first-line immunochemotherapy regimen for advanced stage MZL.
MeSH terms
AdultAgedAntibodies, Monoclonal, Murine-Derived/*therapeutic useAntineoplastic Agents/*therapeutic useDisease-Free SurvivalDrug Therapy, Combination/*methodsFemaleGlucocorticoids/therapeutic useHumansLymphoma, B-Cell, Marginal Zone/*drug therapy/pathologyMaleMiddle AgedPrednisolone/*therapeutic useRepublic of KoreaSurvival RateVincristine/*therapeutic use
DOI
10.1007/s00277-011-1337-6
PMID
21922208
Appears in Collections:
Journal Papers > School of Medicine / Graduate School of Medicine > Hematology-Oncology
AJOU Authors
김, 효철
Files in This Item:
fulltext not available.txtDownload
Export
RIS (EndNote)
XLS (Excel)
XML

qrcode

해당 아이템을 이메일로 공유하기 원하시면 인증을 거치시기 바랍니다.

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse